Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below 50 Day Moving Average - Here's Why

Key Points

• Sensus Healthcare shares slipped below their 50-day moving average of $3.10, trading as low as $3.10 before closing at $3.15. The company has a market capitalization of about $51.9 million.
• Analyst sentiment remains cautiously positive, with an overall “Moderate Buy” rating and a consensus price target of $5.83. However, Lake Street Capital lowered its target to $4.00, while Weiss Ratings downgraded the stock’s sell rating.
• The company reported weak quarterly results, including a loss of $0.53 per share versus an expected loss of $0.12 and revenue of $2.29 million versus estimates of $4.60 million. Insiders have nevertheless purchased 120,171 shares over the past three months.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.10 and traded as low as $3.10. Sensus Healthcare shares last traded at $3.15, with a volume of 8,164 shares.

Analyst Ratings Changes

A number of research firms have issued reports on SRTS. Alliance Global Partners restated a "buy" rating on shares of Sensus Healthcare in a report on Monday, August 17th. Lake Street Capital decreased their price target on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $5.83.

Sensus Healthcare Stock Performance

The firm has a market capitalization of $51.85 million, a P/E ratio of -3.35 and a beta of 1.13. The firm's 50-day moving average is $3.10 and its 200 day moving average is $3.45.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Insider Transactions at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta acquired 27,304 shares of the company's stock in a transaction on Monday, August 31st. The shares were purchased at an average price of $3.54 per share, for a total transaction of $96,656.16. Following the completion of the purchase, the director directly owned 294,784 shares of the company's stock, valued at approximately $1,043,535.36. This represents a 10.21% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have bought 120,171 shares of company stock valued at $405,230. Company insiders own 10.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC bought a new stake in shares of Sensus Healthcare during the 2nd quarter valued at $49,000. XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the 4th quarter valued at $77,000. Jane Street Group LLC bought a new position in shares of Sensus Healthcare in the 4th quarter valued at $79,000. Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $219,000. Finally, State Street Corp boosted its position in Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company's stock valued at $276,000 after buying an additional 3,400 shares in the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.